See more : Shenzhen Coship Electronics Co., Ltd. (002052.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Emclaire Financial Corp (EMCF) Income Statement Analysis – Financial Results
- Evergy, Inc. (EVRG) Income Statement Analysis – Financial Results
- BLB Limited (BLBLIMITED.NS) Income Statement Analysis – Financial Results
- ActBlue Co., Ltd. (300816.SZ) Income Statement Analysis – Financial Results
- Chengdu Spaceon Electronics Co., Ltd. (002935.SZ) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
| General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
| Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
| Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
| Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
| EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
| Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
| Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
| Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder and CEO, will...
Vera Therapeutics (VERA) Sees Hammer Chart Pattern: Time to Buy?
Vera Therapeutics (VERA) has been struggling lately, but the selling pressure may be coming to an end soon.
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, Founder and...
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today the upcoming presentation of clinical data for the...
Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today that it is scheduled to host a key...
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, today reported its financial results for the second quarter ended...
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience and proven track record in strategic investments, equity capital markets, and partnerships Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience...
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Completed an initial public offering with net proceeds, including the exercise of the underwriters' option in full, of approximately $48.4 million in May 2021 - - - Expanded the management team to support initiation of atacicept clinical development program -...
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate...
Source: https://incomestatements.info
Category: Stock Reports